Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HLX10 plus platinum-taxane chemotherapy versus placebo plus chemotherapy as first-line treatment for recurrent, progressive, or metastatic cervical cancer
CTR20210468Phase 3Terminated
- Sponsor
- HyBioPharma
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in Cervical Cancer (CC), sponsored by HyBioPharma. Started Mar 2021; status: terminated.
02
Drugs
serplulimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20210468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210468.